RecruitingPhase 1NCT07444385
A Study to Evaluate the Safety and Pharmacokinetics of AD-116 and AD-1161 in Healthy Adult Male Subjects
An Open-Label, Randomized, Single-Dose, Two-Sequence, Two-Period Crossover Clinical Trial to Evaluate the Safety and Pharmacokinetics of AD-116 and AD-1161 in Healthy Adult Male Volunteers Under Fed Conditions
Sponsor
Addpharma Inc.
Enrollment
44 participants
Start Date
Feb 26, 2026
Study Type
INTERVENTIONAL
Conditions
Summary
A Study to Evaluate the Safety and Pharmacokinetics of AD-116 and AD-1161 Under Fed Conditions in Healthy Adult Male Subjects
Eligibility
Sex: MALEMin Age: 19 Years
Inclusion Criteria2
- Body weight equal to or greater than 50kg and Body mass index (BMI) between 18.0 kg/m2 and 30.0 kg/m2 at the time of screening visit
- The Age equal to or greater than 19 in healthy adult male volunteers at the time of screening visit
Exclusion Criteria2
- Participation in another clinical study with an investigational drug within the 6 months from scheduled first administration
- Other exclusions applied
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGAD-116, AD-1161
Single-dose oral administration of AD-116 or AD-1161, according to randomized sequence.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07444385
Related Trials
Ambulatory Long Length URodynamics Evaluation
NCT074250157 locations
OPtilume™ BPH Catheter SystEm for Treatment of Men eXperiencing Symptomatic BPH
NCT065604769 locations
A Prospective, Multicenter, Open-label Study of the Beacon Platform for Holmium Laser Enucleation of the Prostate (HoLEP)
NCT066681423 locations
Sacral Neuromodulation for Male Overactive Bladder (MOAB)
NCT0651114119 locations
Stop or Ongoing Oral Anticoagulation in Patients Undergoing Pvp (SOAP)
NCT032972811 location